The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study - 21/06/16
Funding: This work was supported by a grant from Ministry of Science and Technology, Taiwan (formerly National Science Council; grant numbers, MOST 104-2314-B-002 -117 -MY3), but had no other study sponsors. The researchers were independent of the funders in designing the study, data collection and analysis, interpreting the results, writing the manuscript and deciding to submit the article for publication. |
|
Disclosures: Dr Tsen-Fang Tsai has conducted clinical trials or received honoraria for serving as a consultant for Pfizer Pharmaceuticals, Serono International SA (now Merck Serono International), UniPharma/Biogen Idec, Galderma, Celgene, Novartis Pharmaceuticals, and Janssen-Cilag Pharmaceutical, and has received speaking fees from AbbVie. Dr Chiu has received speaking fees from AbbVie, Janssen-Cilag Pharmaceutical, and Pfizer. |
Vol 75 - N° 1
P. 224-226 - juillet 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?